Table 2 Univariate analysis of clinical and histopathologic prognostic factors for locoregional control

Family history of breast cancer

1.0

   No

42

70 [56–87]

1

   Yes

11

NA

1 [0.22–4.59]

Age (continuous variable)

0.38

0.94 [0.83–1.07]

Age (years; dummy variable)

0.57

   > 35

16

73 [59–90]

1

   ≤ 35

37

60 [32–100]

1.37 [0.47–4.0]

Clinical tumor stage

0.71

   cT1

31

70 [53–91]

1

   cT2

22

74 [56–96]

0.81 [0.28–2.39]

Histologic T stage

0.55

   pT1

34

70 [54–91]

1

   pT2

14

70 [49–100]

0.71 [0.24–2.13]

Surgical margin

0.70

   ≥ 3 mm

32

61 [43–86]

1

   < 3 mm

17

81 [64–100]

0.81 [0.27–2.37]

Lymphovascular invasion

0.78

   Absent

33

71 [56–91]

1

   Present

17

71 [50–100]

1.18 [0.36–3.87]

Histologic N stage

0.54

   pN0

31

63 [47–84]

1

   pN1

16

78 [53–100]

0.49 [0.13–1.77]

   pN2

6

80 [52–100]

0.77 [0.17–3.52]

Histologic type

0.14

   Ductal

46

75 [63–90]

1

   Lobular

6

33 [7–100]

2.61 [0.72–9.53]

Estrogen receptors (ERs)

0.14

   ER^-

10

90 [73–100]

1

   ER⁺

37

63 [47–85]

4.28 [0.55–33.27]

Progesterone receptors (PR)

0.84

   PR^-

9

71 [43–100]

1

   PR⁺

38

69 [53–88]

1.18 [0.26–5.27]

Hormone receptors (HRs)

0.48

   ER^- and PR^-

7

86 [63–100]

1

   ER⁺ or PR⁺

40

67 [52–86]

2.1 [0.06–3.72]

Histopathologic index

0.59

   Grade 1–2

14

64 [35–100]

1

   Grade 3

36

73 [59–91]

0.70 [0.39–5.19]

Systemic therapy

0.35

   None

16

54 [33–86]

1

   ChT

23

85 [70–100]

0.47 [0.15–1.49]

   ChT + HT

14

43 [11–100]

0.48 [0.12–1.90]

Total RT dose^b

0.27

   ≥ 60 Gy

43

76 [59–97]

1

   < 60 Gy

13

50 [28–88]

1.8 [0.63–5.15]